Search the Newsreel

Kincora Copper Limited (KCC.XA) recent insider transactions

Cencora (COR) Stock May Be 38% Undervalued As Cash Flow Holds Up

Cencora (COR) stock appears to be significantly undervalued, trading at a 38% discount to its estimated intrinsic value according to a Discounted Cash Flow (DCF) model, and also showing as undervalued based on its P/E ratio compared to industry averages. Despite strong long-term returns, …

XS307124637 Bond Profile — Key Metrics

This article provides a detailed profile of the XS307124637 bond issued by Cencora, Inc., outlining key metrics such as its coupon rate of 3.63%, maturity date of May 22, 2032, and an outstanding amount of 500 million EUR. It also includes a description of …

Net debt of Cencora, Inc. – HAM:ABG

This article provides financial information for Cencora, Inc. (HAM:ABG) focusing on its net debt. It specifies that the market is closed with no trades and gives an overview of available financial data. The content primarily comes from TradingView, referencing various data providers.

Price to cash flow ratio of Cencora, Inc. – HAM:ABG

This article provides financial information for Cencora, Inc. (HAM:ABG) on TradingView, specifically focusing on its price-to-cash-flow ratio. It indicates that the market is currently closed with no trades, and offers various tools and resources available on the TradingView platform for financial analysis.

Announcement of the total number of voting rights as at 31 July 2026

KBC Ancora Regulated information, Leuven, 31 July 2026 (17.40 hrs CEST) Announcement of the total number of voting rights as at 31 July 2026 In application of Article 15 of the Act of 2 May 2007 on the disclosure of major shareholdings in issuers …

Cencora (COR) Remains Attractive Despite Temporary Headwinds

Carillon Tower Advisers, an investment management company, released its second-quarter 2026 investor letter for the "Carillon Eagle Mid Cap Growth Fund". A copy of the letter is available to download here. Mid-cap stocks delivered strong results, with the Russell Midcap® Growth Index rising 14.55% …

Countdown to Cencora (COR) Q3 Earnings: A Look at Estimates Beyond Revenue and EPS

Wall Street analysts expect Cencora (COR) to post quarterly earnings of $4.37 per share in its upcoming report, which indicates a year-over-year increase of 9.3%. Revenues are expected to be $84.89 billion, up 5.2% from the year-ago quarter. Over the last 30 days, there …

ABC5748091 Bond Risk Profile

This page provides a detailed profile for the Cencora, Inc. 5.125% 15-FEB-2034 bond (ABC5748091), including an overview of its coupon, redemption, and risks. It highlights key metrics for credit risk assessment, such as security level, inflation protection, and issuer rating, to help users evaluate …

Cencora Inc. stock underperforms Thursday when compared to competitors

Cencora Inc. (COR) shares fell by 2.00% to $312.23 on Thursday, despite a positive trading session for the broader market where the S&P 500 Index and Dow Jones Industrial Average both rose. This marked the stock's second consecutive day of losses.

Cencora, Inc. (COR) Q2 2024 Earnings Report - Results, Call & Slides

Cencora, Inc. (COR) reported its Q2 2024 earnings, beating the consensus EPS estimate by $1.85 with an actual EPS of $66.27 versus an expected $64.42. However, the company missed revenue expectations, reporting $1.19 trillion against an anticipated $1.23 trillion, despite a 7.81% year-over-year revenue …

Cencora (COR) Earnings Expected to Grow: What to Know Ahead of Next Week's Release

Cencora (COR) is expected to report a year-over-year increase in earnings and revenues for the quarter ended June 2026. Analysts anticipate quarterly earnings of $4.37 per share, up 9.3%, and revenues of $84.89 billion, up 5.2%. The company's Zacks Earnings ESP of +1.49% combined …

COR|Cencora Inc|Price:318.710|Chg%:-0.870

This article provides a detailed financial overview of Cencora Inc (COR), including its stock price, market cap, P/E ratio, and upcoming earnings date. It presents comprehensive quarterly and annual financial statements, highlighting key indicators like EPS, Revenue, Net Profit, Gross Margin, and Debt to …

Good Neighbor Pharmacy® Named #1 in Customer Satisfaction with Chain Drug Store Pharmacies and Most Trusted by JD Power

Recognition coincides with ThoughtSpot, Cencora's flagship annual tradeshow and conference for community care providers CONSHOHOCKEN, Pa., July 29, 2026--(BUSINESS WIRE)--Good Neighbor Pharmacy, a national franchise for independent pharmacies offered through Cencora, has been ranked "#1 in Customer Satisfaction with Chain Drug Store Pharmacies" in …

Cencora Number of Employees 2026 | Employee Count & Headcount Data

Cencora, Inc. (COR) had approximately 50,986 employees worldwide as of March 2026, marking a 1.1% growth from 2023 but a 1.2% year-over-year decline in 2026. The company is actively hiring, with job postings increasing by 42.3% in 2026. North America accounts for the largest …

Why Is Ecora Royalties (LSE:ECOR) Drawing Fresh Market Attention?

Ecora Royalties Delivers Strong Q2 Cash Flow as Critical Minerals Portfolio Drives Growth

Laba Bersih Ancora Indonesia Resources Capai US$ 1,06 Juta di Semester I 2026

Is Cencora (COR) Still Trading At A Discount As Its P E Rerating Gains Pace?

Cencora (COR) is gaining investor attention due to its rising P/E ratio and consistent price gains relative to the S&P 500, despite a mixed share price performance over the past year. The stock is currently considered undervalued by analysts, with a fair value pegged …

Cencora, Inc. (COR) Q4 2023 Earnings Report - Results, Call & Slides

Cencora, Inc. (COR) announced its Q4 2023 earnings, reporting an actual EPS of $2.86 which beat the consensus of $2.81, and actual revenue of $68.92 billion, surpassing the expected $66.25 billion. This represents a 12.67% year-over-year revenue growth. The earnings were announced on November …

How Cencora’s Valuation Re‑Rating At Cencora (COR) Has Changed Its Investment Story

Cencora (COR) has seen a valuation re-rating, with recent stock screens highlighting rising P/E ratios and strong multi-year returns, yet also showing the shares trading at a discount to intrinsic value estimates. This shift in valuation metrics suggests the company is potentially undervalued despite …

Coral Products plc Revenue Breakdown – LSE:CRU

Cencora (COR) Stock Looks Undervalued As Its 167% Five Year Return Builds

Find winning stocks in any market cycle. Join 7 million investors using Simply Wall St's investing ideas for FREE. Cencora stock has delivered a strong 167.1% return over the past 5 years, yet its current valuation still screens as cheap. An intrinsic value estimate …

Cencora Inc (COR) Dividends & Stock Splits: Historical Payouts and Event Timeline

This article provides a historical overview of Cencora Inc (COR) dividends, detailing specific payout amounts, record dates, payment dates, and ex-dividend dates. It highlights that the company has distributed a total of 2.01 billion USD in dividends over the past five years. The listed …

Cencora (COR) Stock Could Be 39% Below Fair Value

Cencora (COR) stock appears undervalued, with its Discounted Cash Flow (DCF) intrinsic value estimated at $502 per share, suggesting a 39.3% discount from its current share price of $305.06. Additionally, Cencora's P/E ratio of 23.3x is lower than the healthcare industry average of 25.5x …

A4EQAC Bond Risk Profile

This page provides a risk profile for the Cencora, Inc. 4.6% 13-FEB-2033 A4EQAC bond, available on Gettex. It outlines key metrics for credit risk assessment, including security level, inflation protection, and issuer rating. Additionally, the page mentions access to exclusive analyst ratings for bonds.

Here's Why You Should Add Cencora Stock to Your Portfolio Now

Cencora (COR) is positioned for growth due to its strong U.S. Healthcare Solutions business and new product launches, despite facing competitive pressures. The company is actively expanding in specialty pharmaceuticals and strengthening its supply chain, supported by favorable industry forecasts. However, challenges include revenue …

Cencora stock holds steady as investors await fresh numbers

Cencora Inc. stock remains focused on its existing financial metrics, with revenue, earnings, and margin profile influencing its valuation. However, the available search results lack fresh market or report figures, making it impossible to create a source-grounded article about new developments. The article explicitly …

Cencora stock trades steady as specialty distribution scale and recent earnings shape investor view

Cencora stock is trading steadily due to the company's significant scale in specialty pharmaceutical distribution and its recent earnings performance. The article highlights Cencora's role as a major US pharmaceutical distributor, emphasizing its growth in specialty distribution, margin stability, and strategic investments in technology …

COR stock consolidates after strong fiscal 2025 results and guidance update

Cencora Inc. (COR) has reported strong fiscal year 2025 results, with multi-billion dollar revenues and increased adjusted earnings per share, positioning it as a key player in pharmaceutical distribution. The company's guidance for future fiscal periods offers insights into anticipated revenue and EPS, crucial …

COR|Cencora Inc|Price:305.030|Chg%:+4.450

Cencora Inc. (COR) shows stable fundamentals and high growth potential, with its valuation considered fairly valued within the Healthcare Equipment & Supplies industry. Institutional ownership is high, and analysts largely rate it as a "Buy" with a target price of $352.43. While its performance …

Cencora stock trades steadily as pharmaceuticals distributor highlights rising revenue and earnings

Cencora stock is trading steadily, reflecting the pharmaceutical distributor's growing revenue and adjusted earnings, as highlighted in its recent quarterly figures. Investors are closely monitoring the company's margins, cash generation, and strategic focus on specialty distribution and services, which offer higher profitability. Cencora positions …

Cencora, Inc. Stock 12‑Month Price Target Raised to $354.58, Implies 17% Upside

Cencora, Inc.'s average stock price target has been raised to $354.58, an increase from $352.5, according to 12 analysts. This new target suggests a potential 17% upside from its current closing price, with individual forecasts ranging from $310 to $412 per share. The consensus …

ETFs Investing in Cencora, Inc. Stocks

This article lists various Exchange Traded Funds (ETFs) that hold Cencora, Inc. (COR) stocks, providing detailed financial information for each. The data includes market value, weight of COR in the fund, issuer, management style, focus, expense ratio, assets under management (AUM), price, change percentage, …

Cencora stock trades near record levels as earnings and guidance underpin healthcare distribution growth

Cencora Inc. stock is trading near record levels, reflecting strong recent earnings and raised guidance in the healthcare distribution business. The company reported significant revenue growth and a 25% increase in adjusted EPS for Q2 2024, leading to an upward revision of its full-year …

Cencora Inc. stock underperforms Monday when compared to competitors

Cencora Inc. (COR) stock fell by 1.27% on Monday, closing at $303.99. This underperformance occurred on a generally poor trading day where the S&P 500 Index and Dow Jones Industrial Average also saw declines. It marked the second consecutive day of losses for Cencora's …